Press Release – SinoMab BioScience

All

2024-4-16

Preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy Confirmed that the therapeutic efficacy of SM17 for treating AD is comparable to that of JAK1 inhibitor with good tolerability and safety

2024-1-4

SinoMab Received HKD6.5 Million Subsidy from HKSTP for the clinical study of atopic dermatitis (“AD”)

2023-12-6

SinoMab Awarded the "Best Small and Medium Cap Company” in the “ 8th Zhitong Caijing Listed Company Awards” Development Potential Recognised by The Capital Market

2023-11-27

SinoMab Completes First Cohort of the Healthy Subjects Dosed in a Phase I Clinical Trial of SM17 in China

2023-11-15

SinoMab Submits Another IND Application for Flagship Product SM03 (Suciraslimab) for the Treatment of Alzheimer’s Disease, Which was Accepted by NMPA CDE

2023-09-19

Dr. Shui On LEUNG , Chairman of SinoMab, was Invited to Attend IFRA 2023 Showcases the Clinical Trial Results of SM03 (Suciraslimab) and Receives International Recognition

2023-09-11

SinoMab’s IND Application of SM17 has once again Received Approval from NAMP Clinical Development Program for the Treatment of AD to be Initiated Shortly

2023-08-14

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP Speeding up Domestic Clinical Trials

2023-06-12

SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE

2023-05-22

SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

2023-04-26

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

2022-11-04

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

2022-07-08

SinoMab Received the Highest Subsidy from HKSTP

2022-06-21

The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

2022-06-15

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

2022-06-09

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

2022-04-20

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

2022-03-14

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

2022-02-16

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

2022-02-07

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

2022-01-11

SinoMab Awared the “Best Small and Mid-Cap Company” and “Best CEO” and the “Listed Company with the Most Growth Potential”

2021-11-30

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

2021-11-25

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

2021-09-17

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

2021-05-26

SinoMab Awarded ''Most Outstanding Biopharmaceutical Company of the Year''

2021-01-15

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

2020-11-23

SinoMab Commenced Construction of its China Headquarters

2020-06-24

SinoMab Acquired a Land Parcel of 43,333 sq.m. in Suzhou Industrial Park

2020-06-10

SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress

2020-03-24

SinoMab Announced 2019 Annual Results

2020-01-10

SinoMab Granted the Most Popular Newly Listed Company Award

2019-11-29

SinoMab BioScience Successfully Listed on Main Board of SEHK

2019-11-20

Sinomab BioScience Announces Latest Progress of its Drug Candidate SM03

2019-11-11

Sinomab BioScience Was Over-Subscribed by approximately 11.87 Times for HKPO

2019-10-30

SinoMab BioScience Limited Announces Proposed Listing on Main Board of HKEx

2024

2024-4-16

Preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy Confirmed that the therapeutic efficacy of SM17 for treating AD is comparable to that of JAK1 inhibitor with good tolerability and safety

2024-1-4

SinoMab Received HKD6.5 Million Subsidy from HKSTP for the clinical study of atopic dermatitis (“AD”)

2023

2023-12-6

SinoMab Awarded the "Best Small and Medium Cap Company” in the “ 8th Zhitong Caijing Listed Company Awards” Development Potential Recognised by The Capital Market

2023-11-27

SinoMab Completes First Cohort of the Healthy Subjects Dosed in a Phase I Clinical Trial of SM17 in China

2023-11-15

SinoMab Submits Another IND Application for Flagship Product SM03 (Suciraslimab) for the Treatment of Alzheimer’s Disease, Which was Accepted by NMPA CDE

2023-09-19

Dr. Shui On LEUNG , Chairman of SinoMab, was Invited to Attend IFRA 2023 Showcases the Clinical Trial Results of SM03 (Suciraslimab) and Receives International Recognition

2023-09-11

SinoMab’s IND Application of SM17 has once again Received Approval from NAMP Clinical Development Program for the Treatment of AD to be Initiated Shortly

2023-08-14

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP Speeding up Domestic Clinical Trials

2023-06-12

SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE

2023-05-22

SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE

2023-04-26

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

2022

2022-11-04

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

2022-07-08

SinoMab Received the Highest Subsidy from HKSTP

2022-06-21

The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

2022-06-15

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

2022-06-09

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

2022-04-20

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

2022-03-14

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

2022-02-16

IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

2022-02-07

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

2022-01-11

SinoMab Awared the “Best Small and Mid-Cap Company” and “Best CEO” and the “Listed Company with the Most Growth Potential”

2021

2021-11-30

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

2021-11-25

SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

2021-09-17

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

2021-05-26

SinoMab Awarded ''Most Outstanding Biopharmaceutical Company of the Year''

2021-01-15

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

2020

2020-11-23

SinoMab Commenced Construction of its China Headquarters

2020-06-24

SinoMab Acquired a Land Parcel of 43,333 sq.m. in Suzhou Industrial Park

2020-06-10

SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress

2020-03-24

SinoMab Announced 2019 Annual Results

2020-01-10

SinoMab Granted the Most Popular Newly Listed Company Award

2019

2019-11-29

SinoMab BioScience Successfully Listed on Main Board of SEHK

2019-11-20

Sinomab BioScience Announces Latest Progress of its Drug Candidate SM03

2019-11-11

Sinomab BioScience Was Over-Subscribed by approximately 11.87 Times for HKPO

2019-10-30

SinoMab BioScience Limited Announces Proposed Listing on Main Board of HKEx